Cargando…

Nuclear medicine imaging and therapy of neuroendocrine tumours

Radiolabelled peptides are used for specific targeting of receptors (over-)expressed by tumour cells. Dependent on the kind of labelling and the radionuclide used, these compounds may be utilised for imaging or for therapy. A concise overview is provided on basic principles of designing and developi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gotthardt, Martin, Dijkgraaf, Ingrid, Boerman, Otto C, Oyen, Wim J G
Formato: Texto
Lenguaje:English
Publicado: e-MED 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1805059/
https://www.ncbi.nlm.nih.gov/pubmed/17114073
http://dx.doi.org/10.1102/1470-7330.2006.9038
_version_ 1782132465790353408
author Gotthardt, Martin
Dijkgraaf, Ingrid
Boerman, Otto C
Oyen, Wim J G
author_facet Gotthardt, Martin
Dijkgraaf, Ingrid
Boerman, Otto C
Oyen, Wim J G
author_sort Gotthardt, Martin
collection PubMed
description Radiolabelled peptides are used for specific targeting of receptors (over-)expressed by tumour cells. Dependent on the kind of labelling and the radionuclide used, these compounds may be utilised for imaging or for therapy. A concise overview is provided on basic principles of designing and developing radiopeptides for these applications. Furthermore, clinical application of these compounds for imaging and therapy is described. Advantages of the method compared to other techniques (such as the use of radiolabelled antibodies or antibody fragments) are discussed as well as pitfalls and limitations.
format Text
id pubmed-1805059
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher e-MED
record_format MEDLINE/PubMed
spelling pubmed-18050592008-10-31 Nuclear medicine imaging and therapy of neuroendocrine tumours Gotthardt, Martin Dijkgraaf, Ingrid Boerman, Otto C Oyen, Wim J G Cancer Imaging Article Radiolabelled peptides are used for specific targeting of receptors (over-)expressed by tumour cells. Dependent on the kind of labelling and the radionuclide used, these compounds may be utilised for imaging or for therapy. A concise overview is provided on basic principles of designing and developing radiopeptides for these applications. Furthermore, clinical application of these compounds for imaging and therapy is described. Advantages of the method compared to other techniques (such as the use of radiolabelled antibodies or antibody fragments) are discussed as well as pitfalls and limitations. e-MED 2006-10-31 /pmc/articles/PMC1805059/ /pubmed/17114073 http://dx.doi.org/10.1102/1470-7330.2006.9038 Text en Copyright © 2006 International Cancer Imaging Society
spellingShingle Article
Gotthardt, Martin
Dijkgraaf, Ingrid
Boerman, Otto C
Oyen, Wim J G
Nuclear medicine imaging and therapy of neuroendocrine tumours
title Nuclear medicine imaging and therapy of neuroendocrine tumours
title_full Nuclear medicine imaging and therapy of neuroendocrine tumours
title_fullStr Nuclear medicine imaging and therapy of neuroendocrine tumours
title_full_unstemmed Nuclear medicine imaging and therapy of neuroendocrine tumours
title_short Nuclear medicine imaging and therapy of neuroendocrine tumours
title_sort nuclear medicine imaging and therapy of neuroendocrine tumours
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1805059/
https://www.ncbi.nlm.nih.gov/pubmed/17114073
http://dx.doi.org/10.1102/1470-7330.2006.9038
work_keys_str_mv AT gotthardtmartin nuclearmedicineimagingandtherapyofneuroendocrinetumours
AT dijkgraafingrid nuclearmedicineimagingandtherapyofneuroendocrinetumours
AT boermanottoc nuclearmedicineimagingandtherapyofneuroendocrinetumours
AT oyenwimjg nuclearmedicineimagingandtherapyofneuroendocrinetumours